Table of Content
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Pipeline Analysis of HIV Drug Candidates
5.2 Treatment Access in Low-Income Countries
5.3 Reimbursement Policy Comparison by Country
5.4 Demographics of HIV Drug Users Worldwide
5.5 Pre-Exposure Prophylaxis (PrEP) Usage Statistics
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. HIV Drugs Market Segmentation, by Drug Class
7.1 Chapter Overview
7.2 Integrase Inhibitors
7.2.1 Integrase Inhibitors Market Trends Analysis (2020-2032)
7.2.2 Integrase Inhibitors Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
7.3.1 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Market Trends Analysis (2020-2032)
7.3.2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
7.4.1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Market Trends Analysis (2020-2032)
7.4.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Combination HIV Medicines
7.5.1 Combination HIV Medicines Market Trends Analysis (2020-2032)
7.5.2 Combination HIV Medicines Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Others
7.6.1 Others Market Trends Analysis (2020-2032)
7.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. HIV Drugs Market Segmentation, by Distribution Channel
8.1 Chapter Overview
8.2 Hospital Pharmacies
8.2.1 Hospital Pharmacies Market Trends Analysis (2020-2032)
8.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Retail Pharmacies
8.3.1 Retail Pharmacies Market Trends Analysis (2020-2032)
8.3.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Online Pharmacies
8.4.1 Online Pharmacies Market Trends Analysis (2020-2032)
8.4.2 Online Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Others
8.5.1 Others Market Trends Analysis (2020-2032)
8.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America HIV Drugs Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.2.4 North America HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.2.5.2 USA HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.2.6.2 Canada HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.2.7.2 Mexico HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe HIV Drugs Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.1.5 Poland
9.3.1.5.1 Poland HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.1.5.2 Poland HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.1.6 Romania
9.3.1.6.1 Romania HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.1.6.2 Romania HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.1.7 Hungary
9.3.1.7.1 Hungary HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.1.7.2 Hungary HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.1.8 Turkey
9.3.1.8.1 Turkey HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.1.8.2 Turkey HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe HIV Drugs Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.4 Western Europe HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.5 Germany
9.3.2.5.1 Germany HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.5.2 Germany HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.6 France
9.3.2.6.1 France HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.6.2 France HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.7 UK
9.3.2.7.1 UK HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.7.2 UK HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.8 Italy
9.3.2.8.1 Italy HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.8.2 Italy HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.9.2 Spain HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.11.2 Switzerland HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.12 Austria
9.3.2.12.1 Austria HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.12.2 Austria HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.3.2.13.2 Rest of Western Europe HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific HIV Drugs Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia Pacific HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.4.4 Asia Pacific HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4.5 China
9.4.5.1 China HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.4.5.2 China HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4.6 India
9.4.5.1 India HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.4.5.2 India HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.4.5.2 Japan HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.4.6.2 South Korea HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4.7 Vietnam
9.4.7.1 Vietnam HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.2.7.2 Vietnam HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4.8 Singapore
9.4.8.1 Singapore HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.4.8.2 Singapore HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4.9 Australia
9.4.9.1 Australia HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.4.9.2 Australia HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.4.10.2 Rest of Asia Pacific HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East HIV Drugs Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.1.4 Middle East HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.1.5 UAE
9.5.1.5.1 UAE HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.1.5.2 UAE HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.1.6 Egypt
9.5.1.6.1 Egypt HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.1.6.2 Egypt HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.1.7.2 Saudi Arabia HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.1.8 Qatar
9.5.1.8.1 Qatar HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.1.8.2 Qatar HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa HIV Drugs Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.2.4 Africa HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.2.5 South Africa
9.5.2.5.1 South Africa HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.2.5.2 South Africa HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.2.6.2 Nigeria HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.2.7 Rest of Africa
9.5.2.7.1 Rest of Africa HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.5.2.7.2 Rest of Africa HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America HIV Drugs Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.6.4 Latin America HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.6.5.2 Brazil HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.6.6.2 Argentina HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.6.7 Colombia
9.6.7.1 Colombia HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.6.7.2 Colombia HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America HIV Drugs Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
9.6.8.2 Rest of Latin America HIV Drugs Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10. Company Profiles
10.1 Gilead Sciences, Inc.
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
110.1.4 SWOT Analysis
10.2 ViiV Healthcare
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 GlaxoSmithKline plc (via ViiV Healthcare)
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 Merck & Co., Inc.
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 Johnson & Johnson (Janssen Pharmaceuticals)
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 AbbVie Inc.
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 Cipla Ltd.
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 Mylan N.V. (now part of Viatris)
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 Hetero Drugs Ltd.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 Emcure Pharmaceuticals Pvt. Ltd.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
